论文信息 - Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors. - 字舞流文

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

M. Janicot | M. Noppe | L. van Hijfte | C. Mackie | M. Page | L. Janssen | Laurence Quéguiner | R. Gilissen | J. Arts | P. Angibaud | E. Freyne | I. Pilatte | V. Poncelet | J. van Dun | M. Verdonck | J. van Gompel | D. Speybrouck | A. Mariën | W. Floren | K. van Emelen | Sandrine Gaurrand | Bruno Roux | Sven van Brandt | P. ten Holte | J. Peeters | L. Decrane | M. Du Jardin | Jacky van Gompel

[1] P. Atadja. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.

[2] M. Zeitz,et al. HDAC inhibitors in models of inflammation-related tumorigenesis. , 2009, Cancer letters.

[3] H. Prince,et al. Clinical Studies of Histone Deacetylase Inhibitors , 2009, Clinical Cancer Research.

[4] P. Gimsing. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor , 2009, Expert opinion on investigational drugs.

[5] L. Thompson,et al. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders , 2008, Nature Reviews Drug Discovery.

[6] M. Binaschi,et al. Histone deacetylase inhibitors: from bench to clinic. , 2008, Journal of medicinal chemistry.

[7] M. Janicot,et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies , 2007, British Journal of Cancer.

[8] P. Reddy,et al. Histone Deacetylase Inhibitors: Novel Immunomodulators , 2007 .

[9] M. Caraglia,et al. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. , 2007, Recent patents on anti-cancer drug discovery.

[10] C. Monneret. Histone deacetylase inhibitors for epigenetic therapy of cancer , 2007, Anti-cancer drugs.

[11] P. Marks,et al. Discovery and development of SAHA as an anticancer agent , 2007, Oncogene.

[12] Kelly A. Nadeau,et al. Dynamic Biphasic Counterion Exchange in a Configurationally Stable Aziridinium Ion: Efficient Synthesis and Isolation of a Koga C2-Symmetric Tetraamine Base , 2007 .

[13] L. Bijnens,et al. Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors , 2006, Molecular Cancer Therapeutics.

[14] Jessica E. Bolden,et al. Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[15] M. Janicot,et al. Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[16] K. Glaser,et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.

[17] Ricky W. Johnstone,et al. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[18] A. Mai,et al. A NEW FACILE AND EXPEDITIOUS SYNTHESIS OF N-HYDROXY-N′-PHENYLOCTANEDIAMJDE, A POTENT INDUCER OF TERMINAL CYTODIFFERECNTIATION , 2001 .

[19] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[20] N. Petasis,et al. A new synthesis of α-arylglycines from aryl boronic acids , 1997 .

[21] Ronald Breslow,et al. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.